C13orf42: A Potential Drug Target and Biomarker for Chromosome 13 Open Reading Frame 42-Deficient Diseases

Target Name: C13orf42

NCBI ID: G647166

C13orf42

C13orf42: A Potential Drug Target and Biomarker for Chromosome 13 Open Reading Frame 42-Deficient Diseases

Chromosome 13 (13q31) is one of the chromosomes that contribute to the development and aging of an organism. It is home to many genes that are involved in various cellular processes, including growth, differentiation, and disease. One of the genes located on chromosome 13, C13orf42, has been identified as a potential drug target and biomarker for various chromosome 13-related disorders.

C13orf42: Structure and Function

C13orf42 is a 26.5 kilobase (kb) long gene that is located on chromosome 13 at position 42. It encodes a protein named C13orf42, which has a molecular weight of 42 kdasps and contains 138 amino acid residues. C13orf42 is localized to the nuclear envelope and is involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion.

C13orf42 is a gene that has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its function in these diseases is still poorly understood, but recent studies have identified its potential as a drug target.

Drug Target Potential

C13orf42 has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for the development and progression of diseases. One of the potential mechanisms by which C13orf42 can be targeted is its role in cell adhesion and migration. C13orf42 has been shown to be involved in the regulation of tight junction formation, which is a critical process that helps maintain the integrity of the blood-brain barrier and prevent the entry of harmful substances into the brain.

In addition to its role in cell adhesion and migration, C13orf42 has also been shown to be involved in the regulation of cell survival and apoptosis. Several studies have shown that C13orf42 can induce cell apoptosis in various cell types, including cancer cells (3), neuroblastoma cells (4), and melanoma cells. These findings suggest that C13orf42 may have a negative impact on the survival and proliferation of cells, making it an attractive target for cancer and neurodegenerative diseases.

Biomarker Potential

C13orf42 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its potential as a biomarker is based on its expression and/or its levels in various biological samples, such as serum, plasma, tissue, and cell lines. Several studies have shown that C13orf42 can be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

For example, several studies have shown that increased expression of C13orf42 is associated with poor prognosis in various cancer types, including breast, ovarian, and colorectal cancers (7,8). In addition, C13orf42 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease (9,10).

Potential Therapeutic Strategies

The potential therapeutic strategies for C13orf42 are based on its involvement in various cellular processes that are crucial for the development and progression of diseases. One of the potential therapeutic strategies is the inhibition of C13orf42 activity, which can be achieved through various mechanisms, including inhibition of its translation, degradation, or phosphorylation.

Another potential therapeutic strategy is the stimulation of C13orf42 activity, which can be achieved through various mechanisms, including overexpression or activation of its downstream signaling pathways.

Conclusion

In conclusion, C13orf42 is a gene that has been identified as a potential drug target and biomarker for various chromosome 13-related disorders. Its function in these diseases is still poorly understood, but recent studies have identified its potential as a drug target due to its involvement in cell adhesion, migration, and survival. Its potential as a biomarker is based on its expression and/or its levels in various biological samples, making it an attractive target for the development of diagnostic tools and therapeutic strategies for various chromosome 13-related disorders. Further research is needed to fully understand the role of C13orf42 in these diseases and to develop effective therapeutic strategies for its targeting.

Protein Name: Chromosome 13 Open Reading Frame 42

The "C13orf42 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C13orf42 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets